A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF-alpha therapies

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF-alpha therapies

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2016

At a glance

  • Drugs Methotrexate (Primary) ; Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms REFLEX
  • Sponsors Biogen; Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00468546).
    • 03 May 2010 Two-year radiographic results have been published in Annals of the Rheumatic Diseases (2010;69:1158-1161 doi:10.1136/ard.2009.119222; published online first 3 May 2010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top